Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 8/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 2/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311280 | 0.93 | POLB (0.33) | POLBHSD17B10CYP3A4CYP2C19 | |
| SCHEMBL20263702 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP | |
| SCHEMBL22115954 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP | |
| SCHEMBL31395485 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP | |
| SCHEMBL20263703 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP | |
| SCHEMBL17841870 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP | |
| SCHEMBL17842470 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP | |
| SCHEMBL22841031 | 0.91 | GLP1R (0.33) | POLBHSD17B10GLP1RFAP | |
| SCHEMBL19776684 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP | |
| SCHEMBL19777071 | 0.91 | GLP1R (0.40) | POLBGLP1RFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015831-A1 | ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF | ABGENOMICS INTERNATIONAL INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015831-A1 | ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF | CD22, CD2, CD2BP2 | POLB 4508/4885HSD17B10 2085/4885GLP1R 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.